Caltagirone SpA (CALT)
Sep 20, 2024 - CALT was voluntarily delisted
40.00
-0.04 (-0.10%)
Inactive · Last trade price on Sep 20, 2024
CALT Revenue
Calliditas Therapeutics AB had revenue of 1.09B EUR in the half year ending June 30, 2025, with 14.51% growth. This brings the company's revenue in the last twelve months to 2.22B, up 12.16% year-over-year. In the year 2024, Calliditas Therapeutics AB had annual revenue of 2.11B with 8.54% growth.
Revenue (ttm)
2.22B EUR
Revenue Growth
+12.16%
P/S Ratio
0.48
Revenue / Employee
564,684 EUR
Employees
3,925
Market Cap
1.26B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 2.11B | 165.97M | 8.54% |
Dec 31, 2023 | 1.94B | 3.73M | 0.19% |
Dec 31, 2022 | 1.94B | 364.11M | 23.10% |
Dec 31, 2021 | 1.58B | 141.77M | 9.88% |
Dec 31, 2020 | 1.43B | -22.01M | -1.51% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCALT News
- 1 year ago - Delisting of Calliditas Therapeutics AB (publ) from Nasdaq Stockholm - PRNewsWire
- 1 year ago - Notice of extraordinary meeting of Calliditas Therapeutics AB (publ) - PRNewsWire
- 1 year ago - Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei - PRNewsWire
- 1 year ago - Calliditas Therapeutics AB (publ) (CALT) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Calliditas Interim Report January to June 2024 - PRNewsWire
- 1 year ago - Number of shares and votes in Calliditas Therapeutics - PRNewsWire
- 1 year ago - SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ATRI, CALT on Behalf of Shareholders - Accesswire
- 1 year ago - Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy - PRNewsWire